Current Pain and Headache Reports

, Volume 10, Issue 4, pp 275–278 | Cite as

Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated

Article

Abstract

Chemotherapy-induced neuropathy is one of the most serious non-life-threatening side effects experienced by patients receiving this group of pharmaceutical agents. Although frequently reversible, some patients may remain with symptoms for the remainder of their lives. Early recognition that "numbness and tingling" in the hands and feet of a patient receiving chemotherapy is due to the antineoplastic drug, with subsequent dose reduction or discontinuation of the offending agent, may prevent the development of serious neurologic dysfunction.

Keywords

Ovarian Cancer Neuropathy Clin Oncol Peripheral Neuropathy Amifostine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Floyd JD, Nguyen DT, Lobins RL, et al.: Cardiotoxicity of cancer therapy. J Clin Oncol 2005, 23:7685–7696.PubMedCrossRefGoogle Scholar
  2. 2.
    Kaldor JM, Day NE, Pettersson F, et al.: Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990, 322:1–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Travis LB, Holowaty EJ, Bergfeldt K, et al.: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999, 340:351–357.PubMedCrossRefGoogle Scholar
  4. 4.
    Cavalatti G, Marzorati L, Bogliun G, et al.: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69:203–207.CrossRefGoogle Scholar
  5. 5.
    Visovsky C: Chemotherapy-induced peripheral neuropathy. Cancer Invest 2003, 21:439–451.PubMedCrossRefGoogle Scholar
  6. 6.
    Warner E: Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 1995, 5:161–169.PubMedCrossRefGoogle Scholar
  7. 7.
    Tuxen MK, Hansen SW: Complications of treatment: neurotoxicity to anti-neoplastic drugs. Cancer Treat Rev 1994, 20:191–214.PubMedCrossRefGoogle Scholar
  8. 8.
    Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 349:9–17. Excellent review of chemotherapy-induced peripheral neuropathy.CrossRefGoogle Scholar
  9. 9.
    Peltier AC, Russell JW: Recent advanced in drug-induced neuropathies. Curr Opin Neurol 2002, 15:633–638.PubMedCrossRefGoogle Scholar
  10. 10.
    Roberts JA, Jenison EL, Kim KM, et al.: A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997, 67:172–177.PubMedCrossRefGoogle Scholar
  11. 11.
    Mollman JE: Cisplatin neuropathy. N Engl J Med 1990, 332:126–127.CrossRefGoogle Scholar
  12. 12.
    Moore DH, Donnelly J, McGuire WP, et al.: Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase-II study of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:4207–4213. An interesting clinical model for testing the potential clinical relevance of an agent claimed to be neuroprotective.PubMedCrossRefGoogle Scholar
  13. 13.
    Postma TJ, Heimans JJ, Muller MJ: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739–744.PubMedCrossRefGoogle Scholar
  14. 14.
    Markman M: Limits to the "benefits" from our oncologic interventions: a case report. Gynecol Oncol 2000, 78:261–262.PubMedCrossRefGoogle Scholar
  15. 15.
    Di Maio M, Iaffaioli RV, de Placido de S, et al.: Residual neurotoxicity in patients with ovarian cancer in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trials in Ovarian cancer (MITO-4) retrospective study. J Clin Oncol 2005, 23(suppl):458s.Google Scholar
  16. 16.
    Pace A, Savarese A, Picardo M, et al.: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 1993, 21:927–931. Randomized phase-III trial demonstrating potential benefits of vitamin E, but it is of insufficient size to draw any definitive conclusions.CrossRefGoogle Scholar
  17. 17.
    Argyriou AA, Chroni E, Koutras A, et al.: Vitamin E for prophylaxis against chemotherapy-induced neuropathy. Neurology 2005, 64:26–31. Randomized phase-III trial demonstrating potential benefits of vitamin E, but is of insufficient size to draw any definitive conclusions.PubMedGoogle Scholar
  18. 18.
    Forman AD: Peripheral neuropathy and cancer. Curr Oncol Rep 2004, 6:20–25.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.University of Texas M.D. Anderson Cancer Center (Mail Box #121)HoustonUSA

Personalised recommendations